规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Ko 143, a potent inhibitor specific to ATP-binding cassette subfamily G member 2 (ABCG2/BCRP), exhibits over 200-fold selectivity against P-gp and MRP-1 transporters[1][2]. At a concentration of 10 nM, Ko 143 notably reduces the IC50 of MTX for HEK G2 cells and mouse G2 cells by 2.5 times. However, Ko143 metabolites, ranging from 1-100 μM, do not affect the function of ABC Transporters[1]. The drug resistance reversal in Topotecan-selected mouse MEF3.8/T6400 cells and human IGROV1/T8 cells is achieved by the FTC analogue Ko 143, applied at 0, 1, or 8 times the EC90 concentration of 25 nM[2]. Ko 143 also blocks the BCRP-mediated transport of ZD 4522 in both wild type Madin-Darby Canine Kidney (MDCK) 2-BCRP421CC cells and mutant MDCK2-BCRP421AA cells[3]. |
Animal study | When administered orally at 10 mg/kg, Ko 143 enhances the bioavailability of SKF 104864A in mice and significantly alters the pharmacokinetics of ZD 4522 in rats[2][3]. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.13mL 0.43mL 0.21mL |
10.65mL 2.13mL 1.06mL |
21.30mL 4.26mL 2.13mL |
CAS号 | 461054-93-3 |
分子式 | C26H35N3O5 |
分子量 | 469.573 |
别名 | |
运输 | 蓝冰 |
存储条件 |
粉末 Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 |
DMSO: 105 mg/mL(223.61 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |